Nucryst Pharmaceuticals has shaken up its management and shelved one of its development programs. Nucryst announced that it had "discontinued the development of, and out-licensing initiatives for, the current formulation of NPI 32101 silver to treat inflammatory bowel disease."
David C. McDowell, vice president operations, adds R&D responsibilities to his job description and Edward Gaj has been named vice president marketing. Katherine J. Turner, PhD, vice president research and development, is leaving to explore outside opportunities.
- read Nucryst's release [1]
Links:
[1] http://www.fiercebiotech.com/press-releases/nucryst-announces-management-realignment-and-r-d-portfolio-change-0